U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784959) titled 'Study of NXP900 With Lorlatinib in ALK+ Lung Cancer' on Aug. 20.
Brief Summary: This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
Study Start Date: Aug. 17
Study Type: INTERVENTIONAL
Condition:
ALK Positive
ALK Positive Non-small Cell Lung Cancer
NSCLC
ALK+ Non-Small-Cell Lung Carcinoma
Intervention:
DRUG: NXP900
NXP900 is an orally administered inhibitor of SRC family kinases (SFK)
DRUG: Lorlatinib
Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell l...